Corporate & Investor Presentation slide image

Corporate & Investor Presentation

Big data analysis demonstrates CPAP treatment decreases mortality rates by 39% Objective: to investigate the effects of CPAP therapy use on all-cause mortality in patients with OSA ALASKA study¹ conducted using data from SNDS, one of the largest anonymized claims databases in the world representing over 99% of the French population - ― Included >176,000 people in France New CPAP users aged 18+, initiated treatment Jan'15-Dec'16 Survival probability 1.00 0.98 0.96 0.94 CPAP therapy termination CPAP therapy continuation . OSA patients who continued CPAP therapy over the 3-year study period were 39% more likely to survive than those who discontinued CPAP therapy 1. Pepin, et al. ERJ suppl (ERS) 2021 HR 0.61, 95% confidence interval [CI] 0.57-0.65; Log-rank p<0.01 0 0 1 2 3 Time [years] CPAP treatment is a case of life or death 47 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22 ResMed
View entire presentation